Page 269 of 401: studies 2,681 to 2,690 of 4,006, newest first. Back to the serotonin overview
Feeling Unreal June 22, 2023 Daphne Simeon, Jeffrey Abugel
Abstract This chapter examines the various biological factors that may be involved in depersonalization/derealization (dpdr) and depersonalization/derealization disorder (DDD). The role of sensory association cortical areas and corticocortical dysconnectivity models are discussed, vis-à-vis the perceptual alterations characteristic of the disorder. The role of the limbic system and the...
Health Sciences June 22, 2023 Rapolas Šalaševičius, Gabrielė Pakriaušytė
Klasikiniai psichodelikai – tai natūralios (psilocibinas) arba sintetinės (LSD) medžiagos, stimuliuojančios 5-HT2A receptorius ir sukeliančios pakitusias regos, klausos, kognityvines ar nuotaikos būsenas. Šios medžiagos vis dažniau patraukia mokslo tyrėjų bendruomenės dėmesį dėl jų potencialios naudos pacientams, sergantiems įvairaus spektro psichikos sutrikimais. Atlikę literatūros apžvalgą...
Frontiers in Psychiatry June 20, 2023 Johannes T. Reckweg, Cees van Leeuwen, Cécile Henquet et al. 86 citations
Background Treatment-resistant depression (TRD) is a substantial public health burden, but current treatments have limited effectiveness. The aim was to investigate the safety and potential antidepressant effects of the serotonergic psychedelic drug 5-MeO-DMT in a vaporized formulation (GH001) in adult patients with TRD. Methods The Phase 1 part ( n = 8) of the trial investigated two single...
American Journal of Psychiatry Residents Journal June 7, 2023 Cyle Johnson 2 citations
Sleep paralysis is a parasomnia that occurs when the muscle atonia of rapid eye movement sleep extends into wakefulness and can be accompanied by intense fear and hallucinations. The primary neurophysiological processes that lead to sleep paralysis are well known and include alterations in the gamma-aminobutyric acid, glycine, orexin, and serotonin systems. Despite a universal...
L'Encephale June 2023 Hugo Bottemanne, Alice Arnould, Amaury Najar et al.
Obsessive-Compulsive Disorder (OCD), characterized by the combination of obsession and compulsion, is a clinical and therapeutic challenge. Many patients with OCD do not respond to first-line treatments such as serotonin selective reuptake inhibitors (SSRIs) and exposure and response prevention psychotherapy (ERP). For these resistant patients, some preliminary studies have shown that ketamine,...
Nature Neuroscience June 1, 2023 Rafael Moliner, Mykhailo Girych, Vera Kovaleva et al. 439 citations
Abstract Psychedelics produce fast and persistent antidepressant effects and induce neuroplasticity resembling the effects of clinically approved antidepressants. We recently reported that pharmacologically diverse antidepressants, including fluoxetine and ketamine, act by binding to TrkB, the receptor for BDNF. Here we show that lysergic acid diethylamide (LSD) and psilocin directly bind to...
International Journal of Molecular Sciences May 30, 2023 Tobias Buchborn, Taylor Lyons, Chenchen Song et al. 6 citations
(1) From mouse to man, shaking behavior (head twitches and/or wet dog shakes) is a reliable readout of psychedelic drug action. Shaking behavior like psychedelia is thought to be mediated by serotonin 2A receptors on cortical pyramidal cells. The involvement of pyramidal cells in psychedelic-induced shaking behavior remains hypothetical, though, as experimental in vivo evidence is limited. (2)...
medRxiv May 26, 2023 Tobias P. Whelan, Eileen Daly, Nicolaas A.j. Puts et al. 3 citations preprint
Abstract Clinical trials of pharmacological approaches targeting the core features of autism have failed. This is despite evidence from preclinical studies, genetics, post-mortem studies and correlational analyses linking peripheral and central markers of multiple candidate neurochemical systems to brain function in autism. Whilst this has in part been explained by the heterogeneity of the...
Translational Psychiatry May 23, 2023 Severin B Vogt, Laura Ley, Livio Erne et al. 85 citations
N,N-dimethyltryptamine (DMT) is distinct among classic serotonergic psychedelics because of its short-lasting effects when administered intravenously. Despite growing interest in the experimental and therapeutic use of intravenous DMT, data are lacking on its clinical pharmacology. We conducted a double-blind, randomized, placebo-controlled crossover trial in 27 healthy participants to test...
iScience May 19, 2023 Andres Ort, John W Smallridge, Simone Sarasso et al. 47 citations
Exploring the neurobiology of the profound changes in consciousness induced by classical psychedelic drugs may require novel neuroimaging methods. Serotonergic psychedelic drugs such as psilocybin produce states of increased sensory-emotional awareness and arousal, accompanied by increased spontaneous electroencephalographic (EEG) signal diversity. By directly stimulating cortical tissue, the...